Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals.

Affiliation

Research Centre for the Study of Hepatitis, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy. Electronic address: [Email]

Abstract

Unexpectedly high occurrence or recurrence rate of hepatocellular carcinoma (HCC) has been observed in patients with chronic hepatitis C receiving direct-acting antivirals (DAAs) therapy.

Keywords

ALRI,Albumin,Bilirubin,Cancer immunosurveillance,Cirrhosis,Interferon-free therapy,NLR,PLR,SII,

OUR Recent Articles